Department of Medicine, The University of Texas Southwestern Medical Center, 5959 Harry Hines Blvd, Dallas, TX, 75235, USA.
Parkland Memorial Hospital, Dallas, TX, USA.
Curr Heart Fail Rep. 2024 Dec;21(6):604-614. doi: 10.1007/s11897-024-00676-8. Epub 2024 Jul 30.
To examine the evolving multifaceted nature of cardiogenic shock (CS) in the context of non-cardiac biomarkers that may improve CS management and risk stratification.
There are increasing data highlighting the role of lactate, glucose, and other markers of inflammation and end-organ dysfunction in CS. These biomarkers provide a more comprehensive understanding of the concurrent hemo-metabolic and cellular disturbances observed in CS and offer insights beyond standard structural and functional cardiac assessments. Non-cardiac biomarkers both refine the diagnostic accuracy and improve the prognostic assessments in CS. Further studies revolving around novel biomarkers are warranted to support more targeted and effective therapeutic and management interventions in these high-risk patients.
探讨非心源性生物标志物在心力 竭 衰 竭（CS）中的多方面作用，这些生物标志物可能改善 CS 的管理和风险分层。
越来越多的数据强调了乳酸、葡萄糖和其他炎症及终末器官功能障碍标志物在 CS 中的作用。这些生物标志物更全面地了解 CS 中同时存在的血液代谢和细胞紊乱，并提供了超越标准结构和功能心脏评估的见解。非心源性生物标志物不仅提高了 CS 的诊断准确性，还改善了预后评估。进一步研究新的生物标志物对于支持这些高危患者更有针对性和有效的治疗和管理干预是必要的。
